(A61K31/4422)

Composition including amlodipine and losartan having improved stability // 2628538
FIELD: pharmacology.SUBSTANCE: pharmaceutical composition for cardiovascular disorders prevention and treatment is described. The said composition comprises amlodipine besylate in an amount of 1.7 to 1.72 wt %, potassium losartan in an amount of 12.22 to 12.37 wt %, and propyl gallate in an amount of 0.01 wt %, based on the total weight of the composition. The said composition has the form of a two-layer pill having two separate layers consisting of an amlodipine layer containing amlodipine besylate and propyl gallate and a layer of losartan containing potassium losartan.EFFECT: improved composition stability in combination with simplicity of preparation.6 cl, 21 tbl, 2 dwg, 5 ex
Combined preparation of lercanidipine and atorvastatin // 2617048
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine and pharmacy. Combined preparation of lercanidipine hydrochloride and calcium atorvastatin is disclosed for treating hypertension accompanied by hyperlipidemia, which contains single dose of 5–20 mg of lercanidipine hydrochloride and 10–80 mg of atorvastatin calcium, wherein weight ratio of lercanidipine hydrochloride to atorvastatin calcium is 1:2–4, and method of producing coated tablet containing them.EFFECT: technical result is combined preparation of lercanidipine and calcium atorvastatin according to this invention has higher efficiency at lower dose as compared to combined introduction of tablets with respect to considerable reduction of hypertension and reducing level of lipids; it is characterized by low therapeutic dose and reduction of number of undesired effects, as well as good tolerance and compliance with drug therapy regimen of patients.8 cl, 7 tbl
ethod for correction of innate and adaptive immunity factors dysfunction for chronic renal failure in experiment // 2616213
FIELD: medicine.SUBSTANCE: starting from the 21st day of chronic renal failure simulation, calcium channel blocking amlodipine drug is administered to rats using a pipette at a dose of 0.25 mg/kg per day per animal, for 7 days. Changes in innate and adaptive immunity factors in relation to the performance of laboratory animals who do not receive amlodipine, are recorded. At that, innate immunity cell factors state normalization, phagocytosis and reactive oxygen forms generation ability, intensity of delayed hypersensitivity reaction, increasing of theantibody-forming cells number in the spleen, are established.EFFECT: method application expands information on the chronic renal failure pathogenesis mechanisms, does not require scarce supplies, is available in the research centers practice, is important for calcium channel blockers efficiency analysis for chronic renal failure treatment.2 tbl
ethod of dissolving nifedipine in aqueous medium using nanotechnology; pharmaceutical composition containing nifedipine solution in aqueous medium; method of quantitative determination of nifedipine in solution // 2606858
FIELD: pharmaceutics.SUBSTANCE: invention relates to pharmaceutics, namely to methods of nifedipine dissolution in water medium using nanotechnology, as well as pharmaceutical compositions containing nifedipine poorly soluble in water medium, and to methods for quantitative determination of nifedipine in solution. Method of nifedipine dissolution in water medium involves preparation of aqueous solution containing nifedipine, poloxamer 407, macrogol 400, poloxamer 188 at temperature 20–37 °C. Present invention provides dissolution of nifedipine to concentration of about 0.8–4.0 mg/g, that more than 100 times exceeds limits of given substance solubility in water.EFFECT: invention provides method of quantitative determination of nifedipine in water solution containing given modes and stages.4 cl

System of intraventricular drug delivery to improve outcome after brain damage, violating cerebral blood circulation // 2606169
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine, namely to neurology, neurosurgery and pharmacology, and can be used for therapeutic treatment of delayed state complication, wherein blood gets into subarachnoid space. Application of microdispersed composition is proposed for preparing drug for treating such conditions. Composition contains powder suspension of microparticles, containing therapeutic amount of agent, selected from group consisting of calcium channel antagonist, endothelin antagonist (ET) and antagonist of channels with transitory receptor potential (TRP), impregnated in matrix or on matrix of biopolymer, and pharmaceutical carrier, which gives viscosity to composition. Microparticles have uniform distribution of size of microparticles. Average particle size is 66 μm. Each microparticle contain at least 40 wt% of therapeutic agent. Method of treatment is also disclosed, which involves use of said microdispersed composition. Sterile set comprises microdisperse composition and syringes with suspension and pharmaceutically acceptable carrier. Method for obtaining microdispersed composition involves use of said set.EFFECT: use of inventions provides gradual release of therapeutic agent for long period of time and introduction into brain ventricle so, that therapeutic composition contacts and flows, at least one cerebral artery in subarachnoid space, not entering system of blood flow in amount, which causes undesirable side effects.23 cl, 21 dwg, 6 tbl, 1 ex

Compositions and methods for improvement of forecast of person with subarachnoidal hemorrhage // 2597791
FIELD: medicine.SUBSTANCE: group of inventions relates to a method of treating delayed complications in a patient suffering from brain damage, where blood gets into subarachnoid space brain, involving local administration of a therapeutic amount of a pharmaceutical composition. Pharmaceutical composition contains a liquid suspension from microparticles, including potential-controlled calcium channel blocker and a polymer. Group of inventions also relates to a delivery system for treating delayed complications in a patient, containing said composition; using pharmaceutical composition in an injectable form for preparing a drug for treating delayed complications in a patient suffering from brain damage.EFFECT: group of inventions enables to eliminate side effects associated with system delivery of active substances.50 cl, 2 ex, 17 dwg, 11 tbl

ethod for treating arterial hypertension by inhalation delivery of hypotensive preparation aerosol // 2593016
FIELD: medicine. SUBSTANCE: present invention relates to medicine, particularly to a method for treating arterial hypertension in mammals, including humans, and can be used for emergency treatment of acute hypertension conditions, for example, hypertensive crisis. Disclosed method involves the pulmonary administration of aerosol hypotensive preparation in a therapeutically effective amount consisting of calcium antagonist group in nano-sized aerosol form with the particle size of 5-200 nm and their concentration in the range of 103-108 cm-3. Nifedipine or nisoldipin is used as a hypotensive preparation. EFFECT: technical result: is fast reduction (by 25 %) of blood pressure by inhalation delivery of a drug in the form of nano-sized aerosol, higher efficiency of arterial hypertension treatment due to high bioavailability of used preparations in nano-sized aerosol form and reduction of their therapeutic dose. 1 cl, 7 dwg, 4 tbl
Pharmacological composition for treating proctologic diseases (versions) // 2592366
FIELD: medicine. SUBSTANCE: present invention relates to medicine, in particular to pharmacological compositions for treating proctologic diseases. Pharmacological composition contains 3.3-7.5 wt% methyluracil, 0.13-0.3 wt% of nifedipine, 0.13-0.3 wt% isosorbide dinitrate and 1.3-3 wt% lidocaine and pharmacologically acceptable carrier - balance. Preferably, composition consists of 5 wt% methyluracil, 0.2 wt% nifedipine, 0.2 wt% isosorbide dinitrate, 2 wt% lidocaine and pharmacologically acceptable carrier - balance. Pharmacological composition can be presented in form of gel, ointment, cream, suppositories, suspended gel, lotion, emulsion. EFFECT: pharmacological composition according to invention ensures fast therapeutic effect. 4 cl, 3 ex

Delivery system for extended release of calcium channel blocker // 2575839
FIELD: medicine.SUBSTANCE: presented group of inventions refers to medicine. What is presented is a delivery system for extended release of a calcium channel blocker containing a solid disperse product of the calcium channel blocker in a mixture with poly(lactide-co-glycolides), wherein a mass ratio of first poly(lactide-co-glycolide) and second poly(lactide-co-glycolide) makes from 10:1 to 1:1.5. What is presented is a method of treating or preventing a cerebral vasospasm by depositing this delivery system into an individual's spinal fluid.EFFECT: presented group of inventions provides the effective agents and methods for controlled release of the calcium channel blocker, particularly nicardipine.9 cl, 3 dwg, 4 tbl, 4 ex
ethod of treating cardiovascular diseases // 2570752
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutical industry and represents a pharmaceutical dosage form for treating cardiovascular diseases and introduced once a day, containing a combination of fixed doses of metoprolol or its pharmaceutically acceptable salt in the sustained-release form, amlodipine, or valsartan, or olmesartan, or lisinopril, or enalapril, or their pharmaceutically acceptable salts, and one or more speed-control polymeric excipients containing cellulose polymers or their derivatives, and acrylic acid polymers or their derivatives, which form two layers on metoprolol or their pharmaceutically acceptable salt,wherein the dosage form possesses such a solution profile that less than 6% of metoprolol or its pharmaceutically acceptable salt releases for 1 hour.EFFECT: invention provides min 10% improved blood pressure after 3 months of treatment.20 cl, 10 ex, 18 tbl
Hypotensive means // 2554815
FIELD: medicine.SUBSTANCE: invention represents a hypotensive means, which contains felodipinum as an active component, as well as target additional components: mesoporous silicon dioxide, lactose, hypromeloza. Realisation of the invention ensures the high technological efficiency of the claimed medical means production with the provision of a prolonged release of an active substance with the application of available components. Felodipinum is included into spherical particles with a highly developed mesoporous structure of silicon oxide.EFFECT: increase of stability in storage and protection from unfavorable environmental factors.4 cl, 4 ex

Stable combined pharmaceutical composition // 2549437
FIELD: medicine, pharmaceutics.SUBSTANCE: amlodipine base or its pharmaceutically acceptable salt, preferentially amlodipine besylate, bisoprolol fumarate, a disintegrating agent, a wetting agent, and if necessary additional excipients are homogenised; an antiadhesion agent is added, and the homogenisation procedure is continued; the homogenate is then tabletted by direct compression, or solid gelatine capsule is filled in; the prepared tablets or capsules are packed in moisture-proof protective packaging. The prepared tablets or capsules contain less than 0.5 wt % of active ingredients of compounds of formula .EFFECT: what is described is a method for preparing the stable solid pack dosage form containing the amlodipine base or its pharmaceutically acceptable salt and bisoprolol fumarate.3 cl, 6 tbl, 2 ex

ulti-layered tablet, containing effervescent layer // 2547562
FIELD: medicine, pharmaceutics.SUBSTANCE: claimed invention relates to the pharmaceutical industry and provides a multilayered tablet, containing an effervescent layer, containing hydrochlorothiazide or amlodipine or its salt as an active ingredient, carbonate salt and organic acid, and a telmisartan-containing layer.EFFECT: obtaining the multilayered tablet, containing the effervescent layer.1 dwg, 9 tbl, 9 ex

ethod of treating cardiovascular diseases // 2536058
FIELD: medicine.SUBSTANCE: with the underlying conventional drug therapy, the patient is exposed to millimetre-wave electromagnetic emission at the molecular spectrum frequencies of oxygen emission and absorption spectra with the exposure localised within the xiphoid appendix. The exposure time is 3 minutes continuously within one session. The output emissive power is 500 mcW at the power density on the skin surface of 17.4 mcW/cm2. A distance of the exposure point and an object is specified to be equal to 4 cm. The therapeutic course makes 7-10 sessions, one session a day.EFFECT: higher therapeutic effectiveness in patients with angina or arterial hypertension ensured by the antihypertensive and antianginal effect resulted from the specified mode of the terahertz exposure.2 ex

Pharmaceutical compositions containing s-amlodipine nicotinate and using them in treating cerebrovascular disorders // 2516922
FIELD: medicine.SUBSTANCE: invention describes using S-amlodipine nicotinate in treating cerebrovascular disorders specified in a group: haemorrhagic stroke, ischemic stroke, including transient global ischemia. A pharmaceutical composition for treating the cerebrovascular disorders contains S-amlodipine nicotinate as an active ingredient in an effective amount of 0.1 mg to 50 mg per a dose, and pharmaceutically acceptable excipients. The composition represents either a tablet, or a solution for injections.EFFECT: expanding the usage of S-amlodipine nicotinate.2 cl, 3 dwg, 3 ex

ethod of reducing amyloid deposition, amyloid neurotoxicity and microglyosis by (-)-enantiomer nilvadipine // 2490014
FIELD: medicine.SUBSTANCE: group of inventions refers to medicine. A method of reducing Aβ, Aβ deposition, neurotoxicity and microglyosis in an animal or a human suffering a cerebral amyloidogenic disease, involving administering a therapeutically effective amount of enantiomer-rich (-)-nilvadipine into the animal or human. The further methods represent methods of reducing a risk of Aβ, Aβ deposition, neurotoxicity and microglyosis in the animal or human suffering the traumatic cerebral affection by administering (-)-nilvadipine following the traumatic cerebral affection with the treatment continued for a specified period of time. A pharmaceutical composition for reducing Aβ, Aβ deposition, neurotoxicity and microglyosis in the animal or human suffering a cerebral amyloidogenic disease containing the therapeutically effective amount of optically active nilvadipine and a pharmaceutically acceptable carrier with the pharmaceutical composition containing a residue of (-)-nilvadipine as compared to (+)-nilvadipine, particularly at least 90% as compared to (+)-nilvadipine.EFFECT: invention provides higher clinical effectiveness.22 cl, 10 ex, 18 dwg
Combined antihypertensive drug and method for preparing it // 2483728
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to a combined antihypertensive drug containing an agent presented by Amlodipine besilate and Lisinopril dehydrate mixed with an excipient. As the excipient, the specified antihypertensive drug contains microcrystalline cellulose of an average particle size of 90-100 mcm and a bulk density of 0.28-0.33 g/ml; as additives, it contains colloidal silicon dioxide, magnesium stearate and sodium carboxymethyl starch. The invention also refers to a method for preparing the mentioned antihypertensive drug by direct compression.EFFECT: providing a stable drug preparation, more storage-stable, having high producibility, active substance distribution uniformity and bioavailability.8 cl, 2 tbl, 3 ex

Tisolum-based pharmaceutical composition for treatment of anal fissures // 2483721
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to medicine and pharmacology and represents pharmaceutical composition for treatment of anal fissures, including base, medication which reduces spasms of smooth muscles, lidocaine, it contains tisolium-gel as base and nifedipine or nitroglycerin as medication, reducing spasm of smooth muscles, components of composition being in specified ratio in grams.EFFECT: invention provides efficient treatment with reduction of concentration of active substances, reduction of side effects, and reduction of treatment terms.7 ex

Hypotensive combination of valsartan and calcium canal blockers // 2450813
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutics and medicine, and concerns a pharmaceutical combined composition for treating and preventing hypertension in patients with diabetes, ventricular hypertrophy in patients with diabetes for the purpose of delay of progression of diabetic renal diseases or for the purpose of reduction of proteinuria in patients with diabetes, containing the AT1-antagonist valsartan or its pharmaceutically acceptable salt and calcium canal blocker which is presented by amlodipine benzylate, and a pharmaceutically acceptable carrier.EFFECT: preparing the pharmaceutical combined composition for treating or preventing hypertension.3 cl, 3 tbl
Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method for making them // 2449786
FIELD: medicine, pharmaceutics.SUBSTANCE: solid dosage form contains valsartan, amlodipine, hydrochlorothiazide and pharmaceutically acceptable additives and is presented in the form of a two-layer tablet. Quantitative proportions of valsartan, amlodipine and hydrochlorothiazide are selected from the following: 160 mg/12.5 mg/5 mg, 160 mg/12.5 mg/10 mg, 160 mg/25 mg/10 mg, 160 mg/25 mg/5 mg and 320 mg/25 mg/10 mg. Preferentially, amlodipine is used in the form of amlodipine besylate. The two-layer tablet can contain valsartan and hydrochlorothiazide in the first layer, and amlodipine in the second layer, or valsartan in the first layer, and amlodipine and hydrochlorothiazide in the second layer. Also, there are described methods for making a two-layer tablet.EFFECT: two-layer tablet under the invention with the fixed combination of valsartan, amlodipine and hydrochlorothiazide have the biological properties equivalent to those of a free combination of said medical agents.17 cl, 11 tbl, 8 ex

ethod for optimising vascular wall activity in patients with degree i-ii hypertension associating metabolic syndrome suffered eye vessel thrombosis // 2430715
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to cardiology and angiologia, and can be used for optimising vascular wall activity in patients with degree I-II arterial hypertension (AH) associating metabolic syndrome (MS) suffered eye vessel thrombosis. That is ensured by introduction of the preparations pioglitazone and amlodipine with underlying an individually prescribed hypocaloric diet and graduated physical exercises. The hypocaloric diet is calculated in kcal by formula: for women of 18-30 years old - (0.0621 × body weight, kg + 2.0357) × 240, of 31-60 years old - (0.342 × body weight, kg + 3.5377) × 240, over 60 years old - (0.0377 × body weight, kg + 2.7545) × 240, for men of 18-30 years old - (0.0630 × body weight, kg + 2.8957) × 240, of 31-60 years old - (0.0484 × body weight, kg + 3.6534) × 240; over 60 years old - (0.0491 × body weight, kg + 2.4587) × 240. The graduated physical exercises represent morning hygienic gymnastics, therapeutic exercises and graduated physical exercises throughout a day. The preparations pioglitazone 30 mg and amlodipine 10 mg are introduced once a day in the same time. The therapy is performed for 4 months.EFFECT: method provides correction of reduced vascular wall function in the patients with degree I-II AH associating MS suffered eye vessel thrombosis for 4 months and allows avoiding vascular complications in such patients.1 dwg, 1 tbl, 2 ex

ethod of correcting vessel wall dysfunctions in patients with arterial hypertension of iii degree with metabolic syndrome after eye vessel thrombosis // 2428162
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to cardiology and angiology, and can be used for correction of vessel wall dysfunctions in patients with arterial hypertension (AH) of III degree with metabolic syndrome (MS), who had eye vessel thrombosis. For this purpose, at the background of individually selected hypocaloric diet and dosed physical exercise medications pioglitazone, lisinopril and amlodipine are introduced. Hypocaloric diet is calculated in kcal by formula: for women of 18-30 years - (0.0621 × body weight, kg + 2.0357) × 240, 31-60 years - (0.342 × body weight, kg + 3.5377) × 240, over 60 years - (0.0377 × body weight, kg + 2.7545) × 240, for men of 18-30 years - (0.0630 × body weight, kg + 2.8957) × 240, 31-60 years - (0.0484 × body weight, kg + 3.6534) × 240; over 60 years - (0.0491 × body weight, kg +2.4587) × 240. Dosed physical exercise includes morning hygienic gymnastics, exercise therapy and dosed physical exercises during the day. Medication pioglitazone is introduced in dose 30 mg 1 time per day, lisinipril in dose 10 mg 1 time per day and amlodipine 10 mg 1 time per day at the same time of the day. Treatment is carried out for 4 months.EFFECT: method ensures correction of attenuation of vessel wall functions in patients with AH of III degree with MS, after eye vessel thrombosis during 4 months and makes it possible to avoid vascular complications in such patients.1 dwg, 1 tbl, 1 ex

Solid medication of olmesartan medoxomil and amlodipine // 2423975
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to stable solid medication, containing olmesartan medoxomil and amlodipine or its pharmaceutically acceptable salt. Said solid medication is, in fact, free of reducing sugars. Stable solid medication optionally can additionally contain hydrochlortiazide or its pharmacologically acceptable salt. Medicinal form is intended for treatment or prevention of diseases caused by hypertension.EFFECT: solid medicinal form in accordance with invention has improved solubility properties in comparison with lactose-containing composition.42 cl, 2 dwg, 4 tbl, 2 ex

(s)-(-)-amlodipine camsylate or its hydrate and pharmaceutical composition including them // 2403241
FIELD: medicine, pharmaceutics.SUBSTANCE: claimed invention relates to (S)-(-)-amlodipine camsylate of formula , where camphorsulfonic acid represents (1S)-(+)-10- camphorsulfonic acid or (±)-10- camphorsulfonic acid, as well as to its hydrate and to pharmaceutical composition, including them, which can be applied in treatment of cardiovascular diseases.EFFECT: high photostability and solubility.8 cl, 3 ex, 5 tbl, 4 dwg
ethod of normalisation of cardiovascular system functional reactivity in case of arterial hypertension with type ii diabetes mellitus // 2398560
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to hematology, cardiology, endocrinology, and can be used for optimisation of cardiovascular system (CVS) functional reactivity in patients with arterial hypertension and type II diabetes mellitus. For this purpose, first evaluation of state of CVS functional reactivity under psychoemotional load is carried out. Systolic, diastolic, mean dynamic (APm.dyn.) pressure, heart rate (HR) are registered. On the basis of said parametres index of functional reactivity (IFR) before and after load is determined by formula IFR=( APm.dyn.xHR)/100 (conv.units). Treatment is administered in IFR increase is more than 20 conv.units. Treatment combines daily swimming in swimming pool for not less than 15 minutes per day, morning hygienic gymnastics, therapeutic-prophylactic gymnastics and fractional physical exercises during the day, as well as intake of valsartan 80 mg, amlodipine and pioglitazone 30 mg 1 time in the morning. Treatment duration is not less than 3 months.EFFECT: method allows to diagnose disorders of CVS functional reactivity in due time, and combination of claimed treatment methods allows to correct it efficiently, which favours prevention of complications of arterial hypertension with type II diabetes mellitus.1 ex
ethod of optimisation of cardiovascular system functional reactivity in case of arterial hypertension in elderly and senile age // 2398559
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to cardiology, and can be used for optimisation of cardiovascular system (CVS) functional reactivity. Method is realised in the following way: evaluation of state of CVS functional reactivity is carried out under psychoemotional load, for which purpose systolic, diastolic, mean dynamic (APm.dyn.) pressure, heart rate (HR) are registered. On the basis of these data index of functional reactivity (IFR) before and after load is determined by formula: IFR=(APm.dyn.xHR)/100 (conv.units). If IFR value increase is more than 20 conv.units, administered is combination of daily swimming in swimming pool for not less than 15 minutes per day, lisinopril 10 mg in the morning 1 time and amlodipine 5 mg in the morning 1 time for not less than 3 months.EFFECT: method allows to normalise CVS functional reactivity due to potentiation of their medicinal action in patients of elderly and senile age with arterial hypertension during three months of treatment.2 ex

edication for arterial hypertension and cardiac dysrhythmia treatment // 2391980
FIELD: medicine.SUBSTANCE: invention belongs to the field of medicine, notably to remedy for arterial hypertension and cardiac dysrhythmia treatment, which includes water-soluble complex of nifedipine (dimethyl ether of 2,6-dimethyl-4-(2ґ-nitrophenyl)-1,4-dihydropiridin-3,5-dicarboxylic acid) with polysaccharide, namely arabinogalactan, obtained as a result of mechanochemical activation of hard components mix with weight ratio nifedipine/arabinogalactan 1:(10-40) in a planetary mill at acceleration 60 g. Complex shows higher antihypertensive activity in tenfold lower dose of nifedipine, and high dysrhythmic activity in two hundredfold lower dose of nifedipine compared with dose, which brings hypotensive effect. Besides complex has higher water solubility.EFFECT: remedy for arterial hypertension and cardiac dysrhythmia treatment is offered.1 cl, 2 dwg, 3 tbl, 3 ex
Way of prevention and treatment of cardiovascular complications at patients with chronic disease of kidneys being on hemodialysis, having anuria // 2363472
FIELD: medicine.SUBSTANCE: invention concerns medicine, namely to nephrology, and can be used for prevention and treatment of cardiovascular complications at patients with chronic disease of kidneys which are on hemodialysis HD. Essence of the way: angiotensin converting enzyme and-or blockers of hypertensinogen receptors and-or antagonists of calcium are administered to the patients with anuria. Spironolactone is additiobally administered in a dose of 25 mg a day throughout 6 months. The developed doses and the regimen of spironolactone introduction raise efficiency of the way at the given category of patients at the expense of reliable depression of aldosterone level in blood, correction of endothelial dysfunction and a fibrinolitic link of the hemostasis system.EFFECT: efficiency of the way at the given category of patients at the expense of reliable depression of aldosterone level in blood, correction of endothelial dysfunction and a fibrinolitic link of the hemostasis system.1 tbl, 2 ex

Tableted dosage form of felodipine with modified release, method and composition for making said tableted dosage form and medical application // 2363464
FIELD: medicine.SUBSTANCE: pharmaceutical composition for making tableted dosage form with modified release for oral administration of calcium channel blocker-felodipine contains felodipine or its pharmaceutically acceptable salt, a carrier for modified release and a hydration gel accelerator. The carrier for modified release is a salt of alginic acid with an alkali metal. The hydration gel accelerator is hydroxypropyl methylcellulose.EFFECT: provision for relatively fast (during several hours) release of felodipine, with simultaneous prolonged retention of its concentration in blood plasma at a stable high level, and is characterised by low cost of production.20 cl, 1 dwg, 2 tbl, 3 ex

edical product for treatment of oncologic diseases // 2361587
FIELD: medicine.SUBSTANCE: application of a fluridon herbicide (1-methyl-5 (α,α,α-trifluoro-m-tolyl)-3-phenylpyridinon-4) of the structural formula (I) as an agent for treatment of oncologic diseases with a disposable dosage from 0.1 mg to 5 g on reception to 3 times a day is offered. It is possible to take fluridon in the form of a dry powder or as an aqueous solution in rectal, intravenous or intraperitoneal manner, in the form of ointment, candles, or inhalant. Efficiency of treatment of oncologic diseases is shown: adenocarcinoma, melanoma with metastasises, carcinoma, non-Hodgkin's lymphoma, liver cancer, glioblastoma, and sarcoma.EFFECT: development of a substance which suppresses proliferation of cancer cells more effectively than doxorubicine, does not cause by-effects in patients at its use.8 cl, 5 tbl, 13 ex

Solid medicinal form intended for treatment of arterial hypertensia and stenocardia, and way of its reception // 2359672
FIELD: medicine, pharmaceutics.SUBSTANCE: invention concerns area of a chemicopharmaceutical industry and concerns the solid medicinal form possessing antianginal and hypotensive activity, containing amlodipine besylate and target additives in quality of active substance at a following parity of ingredients, wt %: amlodipine besylate - 6-10, lactose - 65-90, starch potato - 0.3-0.6, sodium croscarmellose - 1.5-3, stearin acid and-or its salts - 0.5-1, pre-gelled starch - the rest.EFFECT: reception of tablets with the lowered total weight.8 cl, 1 ex, 2 tbl
ethod of improvement of visual functions at primary open angle glaucoma with normalised intraocular tension // 2351299
FIELD: medicine.SUBSTANCE: invention concerns ophthalmology and can be used for improvement of visual functions at primary open angle glaucoma with the normalised intraocular tension. Parabulbar introduction of the 5% Mexidol solution is performed within 10-12 days. In addition nimodipine is administered intravenously in a dose of 10 mg once a day within 10-12 days. Noopept is administered perorally in a dose of 10 mg 2 times a day within 1 month.EFFECT: method allows strengthening antioxidising activity and circulation in eye tissues, increasing regenerating effect of nervous fibers.8 tbl, 4 ex
Normalisation method of lipid content in thrombocyte membranes associated with metabolic syndrome // 2345766
FIELD: medicine.SUBSTANCE: correction of lipid composition of thrombocyte membranes in patients suffering from metabolic syndrome (MS) is enabled with three-month individually prescribed hypo-calorie diet, graduated physical activity and preparations Pioglitazone dosed 30 mg once a day, Irbesartan dosed 150 mg once a day and Lerkanidipine dosed 10 mg in the morning.EFFECT: normalisation of lipid composition of thrombocyte membranes in patients suffering from metabolic syndrome and ensured functioning level specific for healthy people resulted from three-month treatment.1 ex
ethod of decreased thrombocyte activity in patients suffering from metabolic syndrome // 2345764
FIELD: medicine.SUBSTANCE: decreased thrombocyte activity in patients suffering from metabolic syndrome is ensured within 2-3 months with complex therapy including individually prescribed hypo-calorie diet, calculated by formula considering age and sex of the patient and combined with introduction of Amlodipine dosed 5 mg once in the morning, Lisinopril dosed 5 mg once in the morning and Atorvastatine dosed 30 mg once in the evening.EFFECT: extended range of methods for effective correction of thrombocyte haemostasis in MS patients, reduced thrombotic complications due to optimal combination of nonmedicamentous therapy and specific medical products introduced in doses specified above during empirically defined course of treatment.2 ex

ethod of vascular wall functional weakening correction associated with metabolic syndrome // 2341262
FIELD: medicine.SUBSTANCE: method is implemented as follows: for 4 months medical complex consisting of low-calorie diet, graduated exercises, Lercarnidipine 10 mg once a day, Lyoglitason 30 mg once a day, Irbesartan 150 mg once at the same time of day are prescribed.EFFECT: choice of certain preparations from the specified pharmacological groups in combination with non-drug treatment allows for corrected weakening of vascular wall functions in patients with suffering from MS due to normalisation of antithrombotic activity of vessels within four months of treatment.1 ex, 1 dwg, 1 tbl
ethod for optimisation of thrombocyte functions in metabolic syndrome patients // 2339380
FIELD: medicine.SUBSTANCE: invention relates to medicine, particularly cardiology and endocrinology; it allows thrombocyte functions optimisation in metabolic syndrome patients. The method includes combination of low-calorie diet, calculated by special formula, and administration of drugs: 10 mg felodipine daily, 6.21 mg spirapryle every morning.EFFECT: allows normalisation of thrombocyte functions, namely, thrombocyte receptivity to aggregation inducers, to the 12th week of treatment.1 ex

ethod for optimisation of thrombocyte receptivity to aggregation inducers in metabolic syndrome // 2339379
FIELD: medicine.SUBSTANCE: invention relates to medicine, particularly to haematology and endocrinology, and deals with optimisation of thrombocyte receptivity to aggregation inducers in metabolic syndrome patients. For this purpose individually selected low-calorie diet, and drugs: 10 mg amploidine every morning, duovit by 1 red tablet and 1 blue one daily, are administered. The course duration is at least 12 weeks.EFFECT: allows normalisation of thrombocyte receptivity to aggregation inducers, resulted in significant reducing the risk of thrombosis complications in metabolic syndrome.2 tbl, 1 ex, 3 dwg
ethod for thrombocyte disirders correction in metabolic syndrome // 2339374
FIELD: medicine.SUBSTANCE: invention relates to medicine, particularly to haematology and endocrinology, and deals with thrombocyte disorders correction in metabolic syndrome patients. For this purpose individually selected low-calorie diet and drug therapy: 5 mg amlodipine daily, 2 mg perindopryl daily are administered. The therapy course is 24 week.EFFECT: primary haemostasis normalisation, helping significantly lower the risk of thrombosis complications in metabolic syndrome cases.1 ex
ethod of normalisation of functional abilities of thrombocytes at metabolic syndrome // 2338536
FIELD: medicine.SUBSTANCE: method includes application of individually picked up hypohigh-calorie diet and preparations nitrendipine 10 mg of 1 time and eprosartan 600 mg of 1 time, at the same time within 24 weeks. Selection of these medicinal preparations in a combination to a hypohigh-calorie diet allows to normalise thrombocyte hemostasis (adhesive function of thrombocytes, their aggregation) to optimise intravascular activity of thrombocytes, level of peroxide oxidation of lipids and antioxidatic security of thrombocytes.EFFECT: invention allows normalising functional abilities of thrombocytes at a metabolic syndrome.1 ex
ethod of correction of nitrogen oxide level in blood of patients with metabolic syndrome // 2338520
FIELD: medicine.SUBSTANCE: method includes application of individually picked up hypohigh-calorie diet, the dosed out exercise stresses and preparations Metforminum of 500 mg 2 times a day, nitrendipine 10 mg in the morning and eprosartane 600 mg in the morning. Application of the specified combination of a diet, physical loads and the given preparations allows normalising in 6 months of treatment synthesis NO in a vascular wall to level of healthy people.EFFECT: invention allows normalising level nitrogen oxide in blood of patients with metabolic syndrome.2 ex
ethod of thrombocyte activity optimisation associated with metabolic syndrome // 2337686
FIELD: medicine; haematology.SUBSTANCE: within 24 weeks there was applied individually prescribed low-calorie diet calculated in kcal by formula: for women aged 18-30 years (0.0621 x body weight, kg + 2.0357) × 240, 31 - 60 years (0.0342 × body weight, kg + 3.5377) × 240, 60 years and more (0.0377 × body weight, kg + 2.7545) × 240, for men aged18-30 years (0.0630 × body weight, kg + 2.8957) × 240, 31 - 60 years (0.0484 × body weight, kg + 3.6534) × 240, 60 years and more (0.0491 × body weight, kg + 2.4587) × 240. Additionally Phelodypine is introduced in dosage 5 mg 2 times a day combined with Carvedilole dosed 25 mg once a day in the morning. Due to complex influence of diet and specific agents from selected pharmacological groups, as well as empirically determined treatment duration, method provides normalisation of thrombocyte haemostasis and, as a result decreased risk of thrombus formation in patients suffering from arterial hypertension associated with metabolic syndrome.EFFECT: thrombocyte activity optimisation associated with metabolic syndrome.1 ex

ethod of accelerated normalisation of arachidonic acid platelet metabolism in patients suffering from metabolic syndrome // 2337681
FIELD: medicine; haematology.SUBSTANCE: method implies that increased thromboxane production diagnosed by three transfer tests with recovered platelet aggregation in simple transfer test more than 37.0%, collagen-aspirin test measure more than 69.0% and/or collagen-imidazole measure more than 59%, requires prescription of four-months multimodality therapy including low-calorie diet, graduated physical activity, medicines Eprosartan 600 mg in the morning and Nitrendipine 10 mg in the morning.EFFECT: combined application of all multimodality components allows for normalisation of arachidonic acid metabolism in patients suffering from arterial hypertension associated with metabolic syndrome.1 tbl, 1 ex
ethod for accelerated optimisation of platelets activity in metabolic syndrome // 2337674
FIELD: medicine, hematology.SUBSTANCE: method consists in long-term complex administration of low-calorie diet, 200 mg of labetalole twice a day, and 2 mg of lacidipine every morning, to correct platelet hemostasis in metabolic syndrome patients. The method allows primary hemostasis normalisation in metabolic syndrome patients during 2 months, due to ADP and ATP levels normalisation, as well as actin and myosin level and assemblage normalisation in platelets.EFFECT: primary hemostasis normalisation in metabolic syndrome patients.1 ex
ethod of cholesterol dicrease in thrombocyte membranes of patients suffering from metabolic syndrome // 2330658
FIELD: medicine.SUBSTANCE: within 12 weeks therapy including individually prescribed low-calorie diet, individually prescribed physical activity, lovastatin introduced in dose 20 mg once for the night, amlodipine 10 mg once at the same time and oligovit one tablet 2 times a day.EFFECT: decreased risk of thrombotic complications is provided due to the most complete normalisation of cholesterol content in thrombocyte membranes.2 ex

ethod of thromboxane-formation normalisation for patients suffering form arterial hypertension associated with metabolic syndrome // 2330655
FIELD: medicine; cardiology.SUBSTANCE: in case patient is diagnosed with increased thromboxane development resulted from three transfer tests while level of thrombocyte aggregation restoration within simple transfer test is higher than 37.0%, indicators of collagen-aspirin test are higher than 69.0% and/or of collagen-imidazole test is higher than 59%, for purposes of thromboxane development correction associated with arterial hypertension and metabolic syndrome, low-calorie diet, graduated physical activity, intake of Lovastatin 20 mg for the night and Amlodipine 10 mg once a day are prescribed for patient within 4 months.EFFECT: provided normalisation of thromboxane formation in thrombocytes.1 tbl, 3 ex

ethod of fast normalisation of arachidonic acid metabolism for patients suffering from arterial hypertension associated with metabolic syndrome // 2330652
FIELD: medicine; cardiology.SUBSTANCE: thrombocyte aggregation is evaluated within in three transfer tests. If aggregation indicators are found in single transfer test in amount 37.1% and more, and/or in collagen-aspirin test - in amount 69.1% and more, and/or in collagen-imidazole test - in amount 59.1% and more, complex treatment is prescribed for 2 months as follows: low-calorie diet, graduated physical exercises, introduction of Atorvastatin in dosage10 mg for the night, Nitrendipine 0.02 g once a day, Metformin in dosage 500 mg 2 times a day and Duovit 1 red and 1 dark blue tablets per day.EFFECT: thrombus formation risk is decreased due to fast and effective normalisation of arachidonic acid thrombocyte metabolism.1 tbl, 2 ex

ethod of trombocyte intravascular activity normalisation for patients suffering from arterial hypertension associated with metabolic syndrome // 2329802
FIELD: medicine.SUBSTANCE: invention refers to medicine, specifically to haematology, cardiology and endocrinology, and concerns thrombocyte intravascular activity normalisation for patients suffering from arterial hypertension associated with metabolic syndrome. For this purpose individually prescribed low-calorie diet is used within 12 weeks combined with Essentiale Forte dosed 1 capsule 3 times a day, amlodypine dosed 10 mg in the morning and Duovit dosed 1 red and 1 dark blue tablet a day. Such method realisation in particular choice of specific polyvitaminic agent provides conditions for therapeutic components potentiating that is manifested in reduction of thrombocyte content in blood and in normalisation of ADF and ATP content in thrombocyte.EFFECT: development of effective method of thrombocyte intravascular activity normalisation for patients suffering from arterial hypertension associated with metabolic syndrome.2 ex, 1 tbl

Pharmaceutical composition including renin inhibitor, calcium channel blocker and diuretic // 2316318
FIELD: medicine.SUBSTANCE: claimed composition contains (i) aliskiren; (ii) amplodipin; and (iii) hydrochlorotiazid. Invention is useful in treatment of condition or disease such as hypertension, heart failure, angina pectoris, Alzheimer's disease, stroke, etc.EFFECT: composition of prolonged therapeutic effect and synergetic action.7 cl

Cyanoguanidine prodrugs // 2312858
FIELD: organic chemistry, medicine, pharmacy.SUBSTANCE: invention relates to novel derivatives of pyridylcyanoguanidine of the formula (I): wherein X1 and X2 represent independently a bond, linear or branched hydrocarbon diradical; Y1 and Y2 represent independently a bond or -O-; Y3 represents oxygen atom (O), -O-C(O)-, N(R8) wherein R8 represents hydrogen atom; R1 represents hydrogen atom, linear or branched alkyl or phenyl; R2 represents aryl, heteroaryl or nonaromatic heterocyclic hydrocarbon radical wherein each is substituted optionally with tetrahydropyranyloxy-, di-(C1-C4-alkoxy)phosphinoyloxy- and (C1-C4)-alkoxycarbonylamino-group; R3 represents hydrogen atom, linear, branched or cyclic hydrocarbon radical substituted optionally with one or more amino- carboxy-, alkoxy-groups, (C1-C4)-alkoxycarbonyl, (C1-C4)-alkoxycarbonylamine or nonaromatic nitrogen-containing heterocyclic hydrocarbon radical substituted optionally with (C1-C4)-alkoxycarbonyl, or compound of the formula: wherein s represents a whole number from 1 to 10; R6 represents hydrogen or optionally substituted nonaromatic hydrocarbon radical; R7 represents independently hydrogen atom or methyl; R4, R5 and A represent hydrogen atom; Z' represents pharmaceutically acceptable anion, such as chloride, bromide, iodide; m and r represent independently a whole number from 0 to 4; n = 0 or 1. Also, invention relates to compound of the formula (II) given in the invention description, to pharmaceutical composition based on these compounds for preparing a drug used in treatment of proliferative diseases, methods for treatment and using.EFFECT: valuable medicinal properties of compounds and pharmaceutical composition.37 cl, 2 tbl, 36 ex
ethod for preventing pneumonias in patients with ischemic insult // 2297829
FIELD: medicine, anesthesiology-resuscitation, neuropathology.SUBSTANCE: it is necessary to carry out oxygenotherapy, intravenous injection of physiological solution and those of hydroxyethyl starch. Also, it is important to inject beta-blocators, heparin, opioids, alpha2-adrenoagonists, antagonists of NMDA-receptors, glucocorticoids, nimotope, actovegin. One should prescribe early enteral nutrition. On stabilizing the parameters of cardio-vascular and respiratory systems it is necessary to inject intravenously the solution of mildronate 10% - 10 ml for 10-14 d once daily and the intake of rheaferon-EC-lipint at the dosage of 10000-15000 U/kg or through a gastric probe for 5 d. The innovation enables to efficiently prevent pneumonia due to adequate immunotherapy of the above-mentioned pathology.EFFECT: higher efficiency of prophylaxis.3 ex, 1 tbl
 
2551134.
Up!